Business
Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)
Collaboration will Increase Access to CAMBIA and SPRIX through Cove’s Innovative, and Continuous Online Physician Care LAKE FOREST, Ill. and NEW YORK, May 05,
About this update from Assertio Holdings, Inc.
[{"type":"text","content":"Collaboration will Increase Access to CAMBIA and SPRIX through Cove’s Innovative, and Continuous Online Physician Care\nLAKE FOREST, Ill. and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT), and Cove, a leading migraine telemedicine platform, today announced a collaboration to make CAMBIA (diclofenac potassium) for oral solution and SPRIX (ketorolac tromethamine) nasal spray available to Cove’s patient population. This collaboration will make it easier for more patients to gain access to high-quality physician care. Using Cove’s online telemedicine platform, patients complete a consultation with a licensed physician who can prescribe a variety of treatment options, including CAMBIA for a patient’s acute treatment of migraine attacks with or without aura in adults and SPRIX for short-term (up to 5 days) management of moderate to moderately severe pain which requires analgesia at the opioid level in adults. “We are thrilled to be working with Assertio to provide CAMBIA and SPRIX as options to the appropriate patients,” said Caroline Hofmann, General Manager of Cove. “We know that patients need more options to treat their conditions and convenient access to quality care.” “Partnering with Cove, a leading telemedicine platform, furthers our strategy by enhancing our foundational digital platform and virtual engagement efforts to better serve our patients,” said Dan Peisert, President and Chief Executive Officer of Assertio. “This is an exciting direct to patient model for those who prefer a convenient, digital telemedicine option.” CAMBIA and SPRIX each belong to a class of medications called non-steroidal anti-inflammatory drugs (NSAIDs) and have a Boxed Warning for serious cardiovascular and gastrointestinal events. Please see the indications and Important Safety Information below. CAMBIA INDICATIONS AND USAGE CAMBIA® (diclofenac potassium) for oral solution is indicated for the acute treatment of migraine attackswith or without aura in adults (18 years of age or older). Limitations of Use:• CAMBIA is not indicated for the prophylactic therapy of migraine.• The safety and effectiveness of CAMBIA have not been established for cluster headache. SPRIX INDICATIONS AND USAGESPRIX® (ketorolac tromethamine) is indicated in adult patients for the short term (up to 5 days)mana...